2026年8月31日 晚上7:42 UTC / 路透社
[1/2] 美国医疗保险与医疗救助服务中心（CMS）主任穆罕默德·奥兹博士于2026年7月21日在美国华盛顿特区卫生与公众服务部的新闻发布会上发言。路透社/凯莉·库珀/资料图
相关公司
礼来公司
诺和诺德公司
8月31日 路透社 —— 美国医疗保险与医疗救助服务中心主任穆罕默德·奥兹博士周一表示，在一项旨在扩大获取这类热门治疗药物的新联邦项目启动后的头两个月里，已有60万老年人注册领取GLP-1类减重药物。
这项被称为“医保过渡项目”的计划于7月启动，数百万美国老年人只需每月支付50美元即可获得肥胖症治疗药物。
通过《每日案卷》新闻简报，将最新法律新闻直接发送到您的收件箱，开启您的清晨。点击此处订阅。
迈克尔·厄尔曼 报道；米歇尔·尼科尔斯 编辑
我们的准则：汤森路透信任原则。
600,000 seniors have signed up for obesity drugs under new Medicare program
August 31, 2026 7:42 PM UTC / Reuters
[1/2]U.S. Center for Medicare & Medicaid Services (CMS) Administrator Dr. Mehmet Oz speaks during a press conference at the U.S. Department of Health and Human Services in Washington, D.C., U.S., July 21, 2026. REUTERS/Kylie Cooper/File Photo
Companies
Eli Lilly and Company
Novo Nordisk A/S
Aug 31 (Reuters) – U.S. Centers for Medicare and Medicaid Services Administrator Dr. Mehmet Oz said on Monday that 600,000 seniors have signed up to receive GLP-1 weight loss medications in the first two months of a new federal program created to expand access to the highly sought-after treatments.
Under the so-called Medicare Bridge program, which launched in July, millions of older Americans qualify for obesity medications at just $50 a month.
Jumpstart your morning with the latest legal news delivered straight to your inbox from The Daily Docket newsletter. Sign up here.
Reporting by Michael Erman; editing by Michelle Nichols
Our Standards: The Thomson Reuters Trust Principles.
发表回复